Ciclopirox
As of the edition of 20 October 2026, Ciclopirox is a small molecule: marketed, first approved in 1982 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Loprox
- First approved
- 1 June 1982 (FR)
- Approvals on record
- 13 in 5 regions
- Holder of the most recent approval
- Bausch Health; 7 holders in all
- Registered trials
- 10, 2 stopped early
- Disease areas
- Skin and connective tissue; Infections; Cancer; Blood and lymph; Immune system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 2 | 0 | 0 | 1 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Earlier holder | 1982 to now |
| Bausch Health | Acquired holder | 1996 to now |
| Almirall | Applicant | 1997 to now |
| Medicis Pharmaceutical | Later holder | 2003 to now |
| Alvogen | Acquired holder | 2021 to now |
| Eurofarma | Acquired holder | 2026 to now |